ClinicalTrials.gg
RecruitingNCT07355075GX-03 in ADUpdated Sep 4, 2026

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

A Phase 2/3 interventional study of GX-03 and Vehicle in Eczema Atopic Dermatitis, Eczema and Atopic Dermatitis, sponsored by Turn Therapeutics. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Turn Therapeutics · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2025, registered Jan 2026).
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 252 studies in Eczema with a site in United States — 34 open to participants now, 48 under way, 9 of them phase 3. Eczema · United States.

Planned enrollment
76th of 217
190 · median 101
Started
2025
with 15 others
Phase 2/3
3 of 252
1 open now
Primary completion
2027-01
later than 11 of 46 live
Registered
236th of 252
by date

Among the 252 studies in Eczema with a site in United States, this one is the 76th largest by planned enrollment of the 217 interventional ones that give a count, is one of 16 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 11 of the 46 other live ones, and was the 236th registered.

Eczema

507 studies on the registry are indexed under Eczema; 91 are open to participants now.

Browse Eczema studies →

Open to participants now

34 of the 252 studies in Eczema with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 252 studies in Eczema with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis (eczema).

Stage 1 (Completed):

Stage 1 comprised an initial cohort of 50 subjects evaluated through Week 8. Following a pre-specified interim analysis conducted under the supervision of Independent Data Monitoring Committee (IDMC), treatment-response patterns, safety profiles, and endpoint parameters were assessed to optimize enrollment criteria and outcome measures for Stage 2.

Stage 2 (Active/Recruiting):

Stage 2 plans to enroll approximately 135 subjects across three baseline EASI severity strata (1.1 to 7.0, 7.1 to 15.9, and 16.0 and above) with a target of at least 120 subjects completing the 8-week treatment period. Enrollment for Stage 2 is specifically enriched for subjects presenting with significant pruritus (baseline Peak Pruritus Numeric Rating Scale [PP-NRS] of 7 or more) and baseline EASI of 1.1 or more.

Read the detailed description

This is a Phase 2, adaptive, randomized, double-blind, vehicle-controlled study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment (a non-systemic formulation containing polyhexanide) compared with matching vehicle control in adult participants with atopic dermatitis (AD).

Stage 1 (Completed):

Stage 1 enrolled 50 participants (53 subjects randomized, 50 completed) using broad severity eligibility criteria (baseline EASI >7 or vIGA-AD 3 or 4) to evaluate treatment behavior and biomarker concordance across a wide spectrum of AD phenotypes. Following completion of the 8-week evaluation period in 50 participants, an unblinded interim review was conducted by an Independent Data Monitoring Committee (IDMC).

Stage 2 (Active / Recruiting):

Guided by Stage 1 findings, Stage 2 prospectively evaluates GX-03 in an expanded cohort of approximately 135 participants (target: 120 completing the study). Stage 2 enrollment is stratified across three baseline EASI severity bands (1.1-7.0, 7.1-15.9, and 16.0 or above) and enriched for participants with severe baseline PP-NRS of 7 or above).

In both stages, eligible participants are randomized in a 1:1 ratio to receive topically applied GX-03 or matching vehicle control self-administered to affected skin areas at least twice daily for 8 consecutive weeks.

Efficacy assessments are conducted at Week 4, and Week 8 using a superiority testing framework. To control the overall Type I error rate across multiple primary and key secondary endpoints in Stage 2, a Hochberg multiplicity adjustment procedure will be applied. Evaluated endpoints include:

  • Week 4 vIGA-AD Success (vIGA-AD Success defined as a score of 0 or 1 with at least 2 grade improvement).
  • Week 4 EASI-75 (EASI-75 defined as at least a 75% reduction in Eczema Area Severity Index)
  • Week 8 EASI-90 (EASI-90 defined as at least a 90% reduction in Eczema Area Severity Index)
  • Week 8 EASI-100 (EASI-100 defined as 100% reduction in Eczema Area Severity Index)

Safety Monitoring:

Safety assessments include treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), local site tolerability monitoring, and concomitant medication reviews across the treatment and follow-up periods.

03

Conditions studied

  • Eczema Atopic Dermatitis
  • Eczema
  • Atopic Dermatitis

Keywords

  • Moderate-Severe AD
  • Moderate-Severe Eczema
  • Eczema
  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants must meet all of the following criteria:

  • Adults aged 18 to 80 years, inclusive
  • Male or female subjects in good general health as determined by medical history
  • Subjects meeting all of the following baseline criteria:

    • Baseline EASI Score of ≥ 1.1
    • Baseline vIGA-AD Score of 3 or 4
    • Baseline PP-NRS Score of ≥ 7
  • Ability to read, understand, and provide written in English
  • Ability to read, understand, and provide written informed consent in English
  • Willingness and ability to comply with study procedures, including study visits and daily topical application
  • Agreement to use only the assigned study product on designated areas of interest for the duration of the study

Exclusion Criteria

Individuals meeting any of the following criteria will be excluded:

  • Pregnant, breastfeeding, or planning pregnancy during the study
  • Presence of any skin condition or dermatologic disease that could interfere with study treatment or assessments
  • Use of systemic or topical therapies, including , within 3 weeks prior to enrollment
  • Use of anti-inflammatory medications (e.g., topical steroids, ibuprofen, celecoxib); steroid nasal or ophthalmic drops are permitted
  • Use of topical medications at the test sites within 72 hours prior to enrollment
  • Damaged or altered skin at or near test sites (e.g., sunburn, tattoos, scars, uneven pigmentation) that could confound evaluations
  • Any medical condition that, in the investigator's judgment, places the subject at undue risk or compromises study integrity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    GX-03

    Treatment Arm

    Combination Product: GX-03

  • Experimental
    Vehicle

    Vehicle Control

    Other: Vehicle

Interventions

  • Combination productGX-03

    Topical ointment

  • OtherVehicle

    Ointment carrier

06

What researchers measure

Primary outcomes

  1. vIGA-AD Success at Week 4

    vIGA-AD Success defined as score of 0 (clear) or 1 (almost clear) with a ≥2-grade improvement from baseline at Week 4. All Primary Outcome measures will be evaluated using the Hochberg-method.

    Time frame: At Day 28 (Week 4)

  2. EASI-75 at Week 4

    75% reduction from baseline in Eczema Area Severity Index (EASI) at Week 4. All Primary Outcome measures will be evaluated using the Hochberg-method.

    Time frame: At Day 28 (Week 4)

  3. EASI-90 at Week 8

    90% reduction from baseline in Eczema Area Severity Index (EASI) at Week 8. All Primary Outcome measures will be evaluated using the Hochberg-method.

    Time frame: At Day 56 (Week 8)

  4. EASI-100 at Week 8

    100% reduction from baseline in Eczema Area Severity Index (EASI) at Week 8. All Primary Outcome measures will be evaluated using the Hochberg-method.

    Time frame: At Day 56 (Week 8)

07

Study locations

1 of 1 sites recruiting
  • ALS Global
    Irving, Texas 75062, United States
    Recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No — Protection of participant privacy and re-identification risks Ongoing regulatory or commercial activities Intellectual property and competitive concerns Resource and practical barriers

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2026
First posted
Jan 21, 2026
StartActual
Jul 11, 2025
Primary completionEst.
Jan 20, 2027
CompletionEst.
Jan 20, 2027
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07355075
Lead sponsor
Turn Therapeutics
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jul 11, 2025
Primary completion
Jan 20, 2027 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Sep 4, 2026

Study contacts

Barry Reece, MS
Contact
barry.reece@alsglobal.com
9728714371

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion